Skip to main content

Table 1 Cohort clinical and pathologic characteristics

From: Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer

  Current clonal dynamics Remaining patients P value
Study cohort In phase II study
Age 0.67
 Median 52 49
 Range 42–69 31–78
Stage at diagnosis of primary breast cancer 0.74
 I 1 (14%) 5 (17%)
 II 4 (57%) 15 (50%)
 III 1 (14%) 7 (23%)
 Iv 1 (14%) 1 (3%)
Germline BRCA status 0.97
 Wildtype 6 (86%) 20 (71%)
 Mutant 1 (14%) 4 (14%)
 Unkown 0 (0%) 4 (14%)
Primary cancer receptor status 0.25
 Triple negative 5 (72%) 23 (82%)
Metastatic biopsy receptor status 1
 Triple negative 7 (100%) 28 (100%)
Metastatic site
 Lung metastases 1 (14%) 13 (46%) 0.1
 Liver metastases 4 (57%) 7 (25%) 0.11
 Bone metastases 5 (71%) 12 (43%) 0.17
Neoadjuvant therapy 0.24
 Recieved 7 (100%) 19 (68%)
Prior lines of metastatic therapy 0.44
 0 1 (14%) 5 (18%)
 1 4 (57%) 14 (50%)
 2 1 (14%) 3 (11%)
 3+ 1 (14%) 6 (21%)